497 reports of this reaction
4.0% of all NEOMYCIN SULFATE reports
#2 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #2 most commonly reported adverse reaction for NEOMYCIN SULFATE, manufactured by Total Resources International. There are 497 FDA adverse event reports linking NEOMYCIN SULFATE to DRUG HYPERSENSITIVITY. This represents approximately 4.0% of all 12,389 adverse event reports for this drug.
Patients taking NEOMYCIN SULFATE who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is moderately reported among NEOMYCIN SULFATE users, representing a notable but not dominant share of adverse events.
In addition to drug hypersensitivity, the following adverse reactions have been reported for NEOMYCIN SULFATE:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 497 FDA reports for NEOMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 4.0% of all adverse event reports for NEOMYCIN SULFATE, making it one of the most commonly reported side effect.
If you experience drug hypersensitivity while taking NEOMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.